Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Cash & Current Investments (2019 - 2025)

Madrigal Pharmaceuticals (MDGL) has disclosed Cash & Current Investments for 13 consecutive years, with $203.8 million as the latest value for Q4 2025.

  • Quarterly Cash & Current Investments rose 94.04% to $203.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $203.8 million through Dec 2025, up 94.04% year-over-year, with the annual reading at $203.8 million for FY2025, 94.04% up from the prior year.
  • Cash & Current Investments for Q4 2025 was $203.8 million at Madrigal Pharmaceuticals, down from $1.1 billion in the prior quarter.
  • The five-year high for Cash & Current Investments was $1.1 billion in Q3 2025, with the low at $99.9 million in Q4 2023.
  • Average Cash & Current Investments over 5 years is $463.9 million, with a median of $303.2 million recorded in 2021.
  • The sharpest move saw Cash & Current Investments tumbled 72.15% in 2023, then surged 329.79% in 2024.
  • Over 5 years, Cash & Current Investments stood at $270.3 million in 2021, then soared by 32.71% to $358.8 million in 2022, then plummeted by 72.15% to $99.9 million in 2023, then grew by 5.11% to $105.0 million in 2024, then soared by 94.04% to $203.8 million in 2025.
  • According to Business Quant data, Cash & Current Investments over the past three periods came in at $203.8 million, $1.1 billion, and $797.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.